U.S. market Closed. Opens in 1 day 10 hours 40 minutes

THRX | Theseus Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 4.06 - 4.07
52 Week Range 2.0500 - 12.37
Beta 3.15
Implied Volatility 109.80%
IV Rank 1.89%
Day's Volume 677,694
Average Volume 849,600
Shares Outstanding 44,649,200
Market Cap 181,498,998
Sector Healthcare
Industry Biotechnology
IPO Date 2021-10-07
Valuation
Profitability
Growth
Health
P/E Ratio -3.03
Forward P/E Ratio N/A
EPS -1.34
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 38
Country USA
Website THRX
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
*Chart delayed
Analyzing fundamentals for THRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see THRX Fundamentals page.

Watching at THRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on THRX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙